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Abstract
EFhd2 is a calcium-binding adaptor protein that has been found to be
associated with pathologically aggregated tau in the brain in Alzheimer
disease and in a mouse model of frontotemporal dementia. EFhd2 has
cell typeYspeciﬁc functions, including the modulation of intracellular
calcium responses, actin dynamics, and microtubule transport. Here we
report that EFhd2 protein andmRNA levels are reduced in human frontal
cortex tissue affected by different types of dementia with and without tau
pathology.We show that EFhd2 is mainly a neuronal protein in the brain
and is abundant in the forebrain. Using short hairpin RNAYmediated
knockdown of EFhd2 expression in cultured cortical neurons, we
demonstrate that loss of EFhd2 affects the number of synapses devel-
oped in vitro whereas it does not alter neurite outgrowth per se. Our
data suggest that EFhd2 is involved in the control of synapse devel-
opment and maintenance through means other than affecting neurite
development. The changes in expression levels observed in human
dementias might, therefore, play a signiﬁcant role in disease onset and
progression of dementia, which is characterized by the loss of synapses.
KeyWords: Alzheimer disease, Cortical neurons, EFhd2, Frontotemporal
dementia, Frontotemporal lobar degeneration, Swiprosin-1, Synapses.
Dementia is a neurodegenerative disease of the aging
brain. It has become widely accepted that the clinical mani-
festations of dementia are strongly correlated with the extent
of synapse loss in affected brain regions (1Y3); this pathologic
hallmark is also observed in other neurodegenerative diseases
(4). Alzheimer disease (AD) and several other neurodegen-
erative conditions, including forms of frontotemporal lobar
degeneration (FTLD) such as frontotemporal dementia (FTD)
with parkinsonism linked to chromosome 17 (FTDP-17) and
FTLD-tau with Pick bodies (Pick disease), are classiﬁed as
tauopathies. In addition to the loss of synapses, they are char-
acterized by the presence of various types of intraneuronal ag-
gregates of the microtubule-binding protein tau in brain regions
that are involved in clinical manifestations, including de-
mentia, aphasia, and behavioral changes (5). Fittingly, recent
ﬁndings indicate that pathologic forms of tau contribute di-
rectly to synaptic degeneration even before their aggregation;
mislocalization and hyperphosphorylation of tau have both
been implicated in synaptic pathology in models of AD, in
conjunction with amyloid-A peptides (6, 7), as well as in
models of FTDs (8, 9). Other forms of FTLD such as FTLD-
TDP Type B do not involve tau aggregation but are mostly
characterized by intraneuronal inclusions containing the trans-
active response-DNA binding protein-43 (TDP-43); these dis-
orders are clinically often associatedmorewith semantic dementia,
behavioral-variant FTD, andmotor neuron disease (5, 10). Despite
the existing detailed clinical descriptions of these different forms
of dementia and established links to underlying genetic muta-
tions, there is still little known about the molecular basis for
their overlapping clinical manifestations and their propensity to
cause neuronal and synaptic pathology in overlapping regions
of the brain in the frontal and temporal lobes.
Studies in a mouse model of FTD and in the brains of
humans with dementia have suggested an association of the
novel calcium-binding adapter protein Swiprosin-1/EF-hand
domain containing protein 2 (EFhd2) with pathologically ag-
gregated tau (11, 12) and have revealed changes in phos-
phorylation of EFhd2 at Ser74 in AD frontal cortex (13). In
addition, changes in EFhd2 protein levels were noted in the
prefrontal cortex of patients with schizophrenia (14), the vic-
tims of suicide (15), and spinal cord lipid raft preparations from
a mouse model for amyotrophic lateral sclerosis/motor neuron
disease (16). Interestingly, its link to pathologic tau and phos-
phorylation changes in frontal cortex tissues in dementia (12, 13)
and the protein expression changes in the frontal cortex reported
by Martins-de-Souza et al (14) and Kekesi et al (15) hint at a
possible functional role for EFhd2 cognitive processes within the
frontal cortex in general.
Mechanisms for the regulation of EFhd2 expression and
its cellular functions in the CNS have not yet been delineated.
In immune cells, EFhd2 protein and mRNA expression were
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found to be under the control of signaling cascades involving
Ca2+, protein kinase C, and nuclear factor-JB (17, 18). As a
calcium sensor, EFhd2 has been identiﬁed as a modulator of
B-cell receptorYinduced Ca2+signaling (19, 20). Other studies
have pointed out an involvement of EFhd2 in actin bundling
and polymerization (21Y23). These data support the idea that
EFhd2 is involved in the spatiotemporal control of signaling
events within the cell by integrating Ca2+-mediated signals
and modulating the cytoskeleton. In agreement with this, it
has recently been established that EFhd2 can be found in
neurites as well as synapses and affect microtubule transport
in neurons (24).
Here, we report that EFhd2 expression levels are altered
in the human frontal cortex affected by different types of de-
mentia with and without tau pathology. Furthermore, we pres-
ent evidence that EFhd2 is directly or indirectly involved in the
formation of synapses in cortical neurons in vitro.
MATERIALS AND METHODS
Reagents and Antibodies
All chemicals were purchased from Sigma (Gillingham,
Dorset, UK), and all cell culture reagents were purchased
from Invitrogen (Paisley, UK), unless stated otherwise.
Ethics Statement (Animals and Human Tissue)
Human brain tissue and parafﬁn sections were obtained
from the Manchester Brain Bank (approved by Newcastle and
North Tyneside 1 Research Ethics Committee [09/H0906/52])
and the Queen Square Brain Bank for Neurological Disorders
(approved by the London Research Ethics Committee [08/
H0718/54]), and human tissueYrelated work was approved by
the University of St. Andrews Teaching and Research Ethics
Committee. Detailed data on the cases used in this study are
shown in the Table.
Wild-type CD1 mice (Charles River Laboratories) were
housed in accordance with Schedule 1 of the UK Animals
(Scientiﬁc Procedures) Act 1986, and procedures were reviewed
and approved by the University of St. Andrews Animal Welfare
and Ethics Committee.
Plasmids and Cloning
A short hairpin RNA (shRNA) sequence targeting EFhd2
(CGTTTGCCTCAGCGGATA) or a nonrelevant shRNA se-
quence targeting green ﬂuorescent protein (GFP) were cloned
as inverted repeats into the lentiviral vector pLKO.1 after
Age1/EcoR1 digest and calf intestinal phosphatase treatment.
Lentiviral envelope vector pSD11 (VSV-G) and packaging
vector pSD16 (Gag-Pro-Pol, RRE-TAT-Rev) were a kind
gift from Dr Paul Reynolds (University of St. Andrews, St.
Andrews, UK). Lentiviral vectors for the expression of en-
hanced GFP (EGFP)-EFhd2 or EGFP alone were a kind gift
from Dr Chan-Duk Jun (Gwangju Institute of Science and
Technology, Gwangju, Republic of Korea).
Cell Culture and Lentivirus Production
Lentigrade 293T cells were cultured in Dulbecco modi-
ﬁed Eagle medium supplemented with 10% fetal calf serum,
2 mmol/L glutamine, 1 mmol/L sodium pyruvate, 100 units/mL
penicillin, and 100 Kg/mL streptomycin. A total of 4  106
cells were plated in 10-cm culture dishes and cotransfected
with 2.1 Kg pSD11, 6.2 Kg pSD16, and 5.7 Kg lentiviral
transfer vectors. At 24 hours posttransfection, cells were rinsed
once with PBS, and 4.5 mL neuronal culture medium was
added to produce lentiviral supernatants. The supernatants were
removed after 24 hours, and 4.5 mL neuronal culture medium
was added again for 24 hours. Lentiviral supernatants were
cleared by ﬁltration through 0.45-Km syringe ﬁlters, snap fro-
zen in liquid N2, and stored at j80-C. Lentiviral titering was
performed on 293T cells according to standard protocols. Pri-
mary cortical neurons were infected with approximately 105
TU/mL of lentiviruses diluted in fresh neuronal culture me-
dium (theoretical multiplicity of infection of 1Y3) for 4 to
6 hours at 37-C at least 48 hours before analysis.
Primary Neuron Culture
Primary neuronal cultures were prepared from Embry-
onic Day 15 mouse embryos. Brains were dissected and placed
into ice-cold dissection medium (Hanks balanced salt solution
[HBSS] w/o Ca2+/Mg2+, 7 mmol/L HEPES, 10 mmol/LMgCl2,
2 mmol/L GlutaMax, 50 units/mL penicillin, 50 Kg/mL strep-
tomycin). Meninges were removed and cortices were separated
from the cerebellum and diencephalon and transferred to ice-
cold dissection medium in a 15-mL centrifuge tube. Dissection
medium was replaced 0.05% trypsin/0.02% EDTA in HBSS
w/o Ca2+/Mg2+and incubated for 25 minutes at 37-C. One
volume of 0.001% DNAse1 in HBSS was added, the contents
were mixed by inversion, and the tissue was left to settle.
Cortices were triturated in 1 mL triturating solution (0.05%
soybean trypsin inhibitor, 0.001% DNAse1, 1% Albumax in
HBSS) and diluted in neuronal culture medium (neurobasal
medium, 1% B-27, 50 units/mL penicillin, 50 Kg/mL strep-
tomycin). Neurons were plated on glass coverslips or Nunc
culture dishes coated with 3 Kg/mL poly-d-lysine (30Y70 kDa)
at a density of 2.5 104 cells/cm2 for imaging. Fifty percent of
the culture medium was changed ﬁrst at 5 days in vitro (DIV)
and then every 3 days. The synaptic compartment was ana-
lyzed at 13 to 16 DIV. Lentiviral infections on neuronal cul-
tures were done at 1 DIV for the analysis of neurite outgrowth
and at 7 DIV for the analysis of synaptic effects.
Protein Extraction and Western Blotting
Two hundred milligrams of tissue was homogenized in
a reaction tube on ice using micropistilles and 1-mL pipette
tips in 5 volumes of RIPA lysis buffer (25 mmol/L Tris-HCl
pH 7.4, 150 mmol/L NaCl, 5 mmol/L EDTA, 0.1% sodium
deoxycholate, 0.1% sodium dodecyl sulfate [SDS], 1% NP-40,
1 mmol/L NaF, 1 complete protease inhibitor [Roche, Bur-
gess Hill, West Sussex, UK], 1 mmol/L phenylmethylsulfonyl
ﬂuoride, 1 mmol/L Na3VO4). Protein from cell cultures was
extracted in RIPA lysis buffer and homogenized by 10 strokes
with a 200-KL pipette tip. Samples were centrifuged at 15,000 g
for 15 minutes at 4-C. The supernatant was removed, and the
protein concentration was measured by Bradford assay. Protein
extracts were snap frozen in liquid nitrogen and stored at
j80-C. For SDSYpolyacrylamide gel electrophoresis (PAGE),
protein samples were thawed on ice and mixed with 4 protein
sample buffer (106 mmol/L Tris-HCl, 141 mmol/L tris-base,
4% SDS, 40% glycerol, 0.51 mmol/L EDTA, 4% dithiothreitol,
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TABLE. Patient Data for Brain Tissues Used in This Study
Description Figure Pathologic Diagnosis Sex
Onset,
years
Age at Death,
years
Duration,
years PMI MRC ID Source
AD 1 1, 2, 5 AD F NA NA NA BBN_3348 MC
AD 2 1, 2, 5 AD F 84 88 4 BBN_3383 QS
AD 3 1, 2, 5 AD M 79 88 9 BBN_3405 MC
AD 4 1, 2, 5 AD F 80 87 7 BBN_3406 MC
AD 5 1, 2, 5 AD M 59 69 10 MC
AD 6 1E, 5 AD (Braak V1) F NA 85 NA 90.2 hours QS
AD 7 1E, 5 AD (Braak V1) M NA 81 NA 72.15 hours QS
AD 8 1E, 5 AD (Braak V1) F NA 62 NA 62.55 hours QS
AD 9 1E, 5 AD with cortical Lewy bodies F NA 70 NA 47.15 hours QS
C 1 1, 2, 4, 5 Control F NA 89 NA BBN_5745 MC
C 2 1, 2, 5 Control F NA 89 NA BBN_5747 MC
C 3 1, 2, 5 Control M NA 89 NA BBN_5749 MC
C 4 1, 2, 5 Control F NA 90 NA BBN_5750 MC
C 5 1, 2, 5 Control F NA 77 NA BBN_3378 MC
C 6 1, 2 Control NA NA NA NA BBN_3340 MC
C 7 1, 2 Control NA NA NA NA BBN_3478 MC
C 8 1E, 5 Control M NA 71 NA 38.5 hours QS
C 9 1E, 5 Control F NA 82 NA 91.8 hours QS
C 10 1E, 5 Control M NA 69 NA 168 hours QS
C 11 1E, 5 Control F NA 80 NA 49.1 hours QS
FTLD 1 3, 5 FTLD-TDP B M 43 45 2 BBN_5661 MC
FTLD 2 3, 5 FTLD-TDP B M 59 66 7 BBN_5718 MC
FTLD 3 3, 5 FTLD-TDP B M 58 69 11 BBN_5721 MC
FTLD 4 3, 5 FTLD-TDP B M 61 65 4 BBN_5764 MC
FTLD 5 3, 5 FTLD-TDP B M 68 74 6 BBN_5729 MC
FTLD 6 3, 5 FTLD-TDP B F 50 52 3 BBN_5732 MC
FTLD 7 3, 5 FTLD-TDP B F 52 70 18 BBN_5756 MC
FTLD 8 3, 5 FTLD-TDP B F 63 65 2 BBN_5771 MC
FTLD 9 3, 5 FTLD-TDP B F 68 73 5 BBN_5772 MC
FTLD-tau 1 1, 2, 5 FTLD-tau (MAPT) M 50 55 5 BBN_5699 MC
FTLD-tau 2 1, 2, 5 FTLD-tau (MAPT) F 52 65 13 BBN_5717 MC
FTLD-tau 3 1, 2, 5 FTLD-tau (MAPT) M 46 53 7 BBN_5733 MC
FTLD-tau 4 1, 2, 5 FTLD-tau (MAPT) F 57 63 6 BBN_5760 MC
FTLD-tau 5 1, 2, 5 FTLD-tau (MAPT) F 52 58 6 BBN_5763 MC
FTLD-tau 6 1, 2, 5 FTLD-tau (MAPT) NA NA NA NA BBN_6081 MC
FTLD-tau 7 1E, 5 FTLD-tau (MAPT) M NA 66 NA 58.1 hours QS
FTLD-tau 8 1E, 5 FTLD-tau M NA 52 NA 52.35 hours QS
FTLD-tau 9 1E, 5 FTLD-tau M NA 66 NA MC
Pick 1 1, 2, 5 FTLD Pick F 50 58 8 60.45 hours BBN_3182 MC
Pick 2 1, 2, 5 FTLD Pick M 73 77 4 BBN_3222 MC
Pick 3 1, 2, 5 FTLD Pick M 59 69 10 BBN_3288 MC
Pick 4 1, 2, 5 FTLD Pick M 67 75 8 BBN_3433 MC
Pick 5 1, 2, 5 FTLD Pick NA NA NA NA BBN_6069 MC
Pick 6 1E, 5 FTLD Pick M NA 68 NA 71.1 hours QS
Pick 7 1E, 5 FTLD Pick M NA 67 NA 127.3 hours QS
Pick 8 1E, 5 FTLD Pick M NA 75 NA 46.8 hours QS
Pick 9 1E, 5 FTLD Pick M NA 67 NA 73.05 hours QS
Pick 10 1E, 5 FTLD Pick M NA 80 NA 74.45 hours QS
Pathologic diagnoses are as provided by the Manchester Brain Bank (MC) or Queen Square Brain Bank (QS). Onset, age at disease onset/diagnosis; duration, disease duration; PMI,
postmortem interval, usually less than 72 hours, exact time given where available. Where available, anonymized Medical Research Council ID numbers (MRC ID) are provided to
enable researchers to ﬁnd the cases used in this study on the MRC Brain Bank Network Web site (http://www.mrc.ac.uk/research/facilities/brain-banks/) should they wish to use these or
similar tissues for future studies.
AD, Alzheimer disease; F, female; M, male; MAPT, microtubule protein-associated tau; NA, not available; Pick, Pick disease.
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0.05 mg/mL bromophenol blue, pH 8.5) and Milli-Q water and
denatured at 95-C for 5 minutes.
Twenty-ﬁve micrograms of protein was separated on
10% or 12.5% SDS-PAGE for 10 minutes at 120 V followed
by 1 hour at 160 V and transferred to 0.2 Km supported ni-
trocellulose or polyvinylidene ﬂuoride membranes (GE Health-
care, Little Chalfont, Buckinghamshire, UK) for 60 to 90minutes
at 25 V. Membranes were rinsed in tris-buffered saline (TBS)
and blocked in TBS/0.1% Tween 20 (TBS-T) containing 1:5
diluted LI-COR blocking buffer (LI-COR Biosciences, Cambridge,
UK) or 5% bovine serum albumin. Primary antibodies diluted
in 1:5 diluted LI-COR blocking buffer were goat anti-EFhd2
(ab24368, 1:1000; Abcam, Cambridge, UK), mouse antiYA-actin
(A1978, 1:10,000; Sigma), mouse antiYglyceraldehyde 3-phosphate
dehydrogenase (GAPDH, G8795, 1:20,000; Sigma), goat anti-
synapsin (C-20, sc-8295, 1:1000; Insight Biotechnology,Middlesex,
UK), and mouse antiYA3-tubulin (G7121, 1:2000; Promega,
Southampton, UK). Antibodies diluted in 5% bovine serum
albumin/TBS-T or TBS-T were rabbit antiYPSD-95 (EP2652Y,
ab76115, 1:3000; Abcam), rabbit antiYmicrotubule-associated
protein 2 ([MAP2] ab32454, 1:500; Abcam), and antiYTau DA9,
RZ3, PHF-1, and CP-13 (1:1Y1:50; kind gifts from Prof. Peter
Davies, Albert-Einstein College of Medicine, Bronx, NY). All
were incubated overnight at 4-C. Membranes were washed 3
5 minutes in TBS-T and incubated with infrared dyeYcoupled
antibodies in TBS-T (IRDye 800CW or IRDye 680RD goat
anti-mouse/anti-rabbit [LI-COR Biosciences] or donkey anti-
goat Alexa Fluor 790 [Jackson Immunoresearch, Suffolk, UK])
for 1 hour at room temperature. Bands were detected using the
LI-COR Odyssey detection system. Densitometry of stained
bands was done in NIH ImageJ software, and values were
normalized to the loading control.
Synaptoneurosome Preparation
Crude synaptoneurosomes were prepared according to
Tai et al (25). Two hundred milligrams of fresh-frozen human
brain tissue was homogenized in a glass dounce homoge-
nizer with 1 mL ice-cold buffer A (25 mmol/L HEPES pH 7.5,
120 mmol/L NaCl, 5 mmol/L KCl, 1 mmol/L MgCl2, and
2 mmol/L CaCl2), supplemented with 2 mmol/L dithiothreitol,
protease inhibitors, and phosphatase inhibitors. The homoge-
nate was passed through 2 layers of 80-Km nylon ﬁlters
(Millipore, Watford, UK), and a 200-KL aliquot of the ﬁltered
homogenate was saved. The saved aliquot was mixed with
200KL water and 70 KL 10% SDS, passed through a 27-gauge
needle, and boiled for 5 minutes to prepare the total extract.
To prepare ﬁltered synaptoneurosomes, the remainder of the
homogenate was passed through a 5-Km Durapor membrane
ﬁlter (Millipore) to remove large organelles and nuclei and
centrifuged at 1,000  g for 5 minutes. The nonsynaptic super-
natant containing cytoplasmic proteins was removed, and the
pellet was washed once with buffer A and centrifuged again,
yielding the synaptoneurosome pellet.
Quantitative Real-time Polymerase Chain Reaction
Total RNA was extracted from 50- to 100-mg tissue
samples using 1mLTri-reagent according to the manufacturer’s
protocol. Three micrograms of RNA was digested with 3 units
DNAse 1 (Promega) in a 10-KL reaction at 37-C for 45 minutes.
The reaction was terminated by addition of 1 KL RQI DNAse
Stop solution (Promega) and incubation for 10 minutes at 65-C.
Complementary DNA was produced from the DNAse-
digested RNA using random hexamer primers and Revert
Aid Reverse Transcriptase (Fermentas, Fisher Scientiﬁc,
Loughborough, UK), according to the manufacturer’s instructions.
Tenmicroliters of qPCR reactions using 1KL 1:20 diluted cDNA
and 200 nmol/L primers (EFhd2 forward: TCGACCTGATGGA
GCTAAAACTCA, EFhd2 reverse: ACACGTTGATGGCCTG
TACCTT; actin forward: CTCGCCTTTGCCGATCC, actin re-
verse: AACATGATCTGGGTCATCTTCTC; GAPDH forward:
CAGTCAGCCGCATCTTCTTT,GAPDH reverse: CCCAATA
CGACCAAATCCGT) and Brilliant III SYBR green reaction
mix (Agilent, Santa Clara, CA) were prepared using a QIAgility
robot and run on a Rotor-Gene cycler using a rotor disc 100
(Qiagen, Manchester, UK). Data of 3 runs with samples run in
duplicate were analyzed with the Rotor-Gene software based on
the $$-Ct method, with both actin and GAPDH used as refer-
ence genes.
Immunocytochemistry
Neurons grown on coverslips were ﬁxed with prewarmed
4% paraformaldehyde solution for 15 minutes at room tem-
perature. Cells were permeabilized with PBS/0.05% Triton
X-100 for 5minutes, and nonspeciﬁc antibody binding sites were
blocked by incubation in PBS/10% horse serum for 30 minutes.
Primary antibodies (rabbit anti-tubulin, T3526, 1:500; Sigma),
mouse antiYA3-tubulin (1:2000), goat antiYsynapsin 1a/b (1:500),
rabbit anti-PSD95 (1:500), and rabbit anti-EFhd2 (ab87006,
1:100; Abcam) were diluted in PBS and incubated overnight
at 4-C, followed by 3  5-minute washes with PBS/0.02%
Tween 20. Fluorochrome-conjugated secondary antibodies
(donkey anti-mouse Alexa Fluor 594/488, bovine anti-goat
Alexa Fluor 488 [Jackson Immunoresearch, Suffolk, UK],
donkey anti-rabbit Alexa Fluor 594 [Invitrogen, Paisley, UK],
Alexa Fluor 594 Phalloidin [A1238, 1:1000; Invitrogen,
Paisley, UK]) were diluted in PBS and incubated for 1 hour at
room temperature in the dark followed by 3 5-minute washes
with PBS/0.02% Tween 20. One microgram per milliliter 4¶,6-
diamidino-2-phenylindole was added to the secondary antibody
solution as a nuclear counterstain. Coverslips were mounted on
microscope slides in Mowiol mounting medium (10% Mowiol-
488, 2.5%glycerol, 1.5%propylgallate, 100mmol/L Tris, pH 8.5).
Immunohistochemistry
For 3,3¶-diaminobenzidine (DAB) staining, 7-Km paraf-
ﬁn sections were rehydrated as follows: 3  5 minutes 100%
xylene, 2  2 minutes 100% ethanol, 2 minutes 80% ethanol,
2 minutes 50% ethanol, 2-minute rinse in tap water. Heat-
induced antigen retrieval was done in boiling 100 mmol/L cit-
rate buffer, pH 6.0 for 10 minutes in a microwave pressure
cooker, followed by 2 washes of the cooled sections in PBS/
0.1% Tween 20 for 5 minutes. Endogenous peroxidases were
blocked with 3% H2O2 for 10 minutes. Nonspeciﬁc antibody
binding sites were blocked with 2.5% horse serum supplied
with ImmPRESSAnti-Rabbit Ig (peroxidase) Polymer Detection
Kit (Vector Laboratories, Peterborough, UK) for 30minutes, and
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rabbit anti-EFhd2 was diluted in 2.5% horse serum in PBS/
0.4% Tx-100 and incubated overnight at 4-C. Sections were
washed 2  5 minutes in TBS/0.02% Tween 20 and incu-
bated with ImmPRESS anti-Rabbit Ig (peroxidase) (Vector
Laboratories) for 1 hour. Staining was visualized using DAB
Peroxidase Substrate Kit (Vector Laboratories) according to
the manufacturer’s instructions. Immunoﬂuorescence staining
was done on 13-Km sections from fresh-frozen adult mouse
brain tissue ﬁxed in 100% acetone at j20-C for 5 minutes.
Nonspeciﬁc antibody binding sites were blocked with 2.5%
horse serum in PBS/0.1% Tx-100 for 30 minutes and rabbit or
goat anti-EFhd2 (Abcam) diluted in 2.5% horse serum in PBS/
0.1% Tx-100 and incubated overnight at 4-C. Sections were
washed 2  5 minutes in PBS/0.02% Tween 20 and incubated
withmonoclonal rabbit anti-NeuN (ab177487; Abcam) or mouse
anti-NeuN (MAB377; Millipore) for 2 hours at room tempera-
ture. Sections were washed 2 5 minutes in PBS/0.02% Tween
20 and incubated with appropriate combinations of donkey anti-
rabbit Alexa Fluor 594 (Invitrogen, Paisley, UK), bovine anti-
goat Alexa Fluor 488, and donkey anti-mouse Alexa Fluor 488
(Jackson Immunoresearch, Suffolk, UK) for 1 hour at room
temperature. Coverslips were mounted using Mowiol mounting
medium (without propylgallate for DAB-stained sections).
Fluorescence Microscopy and Image Analysis
Stained cells were analyzed at a Deltavision imaging
system using an Olympus 60X/1.42, Plan Apo N oil immer-
sion objective. Image stacks with a 0.2-Km-step size were
acquired and deconvolved using SoftWorX Acquisition and
Analysis software. Images were imported into ImageJ using
the Bioformats plugin, and colocalization analysis was per-
formed using the Colocalization analysis plugin on image
stacks. Total numbers of synapsin puncta were determined as
counts of puncta of 0.05- to 1.5-Km2 size and normalized to
the length of the tubulin skeleton. Mature synapses were
quantiﬁed as puncta with colocalization of synapsin 1a/b and
PSD-95 and expressed as a ratio of colocalizing puncta com-
pared with the total number of synapsin puncta. Total neurite
development was quantiﬁed as the area covered by skeletonized
A3-tubulinYstained neurites in 3 DIV cultures, normalized to
the number of cells per ﬁeld of view.
Data Analysis
Statistical analysis was done in Prism statistical soft-
ware (GraphPad, La Jolla, CA). Normality of data sets was
conﬁrmed using D’Agostino-Pearson normality test, and one-
way analysis of variance (ANOVA) with Dunnett post hoc
test or 2-tailed t test was applied depending on the compari-
sons made and indicated in ﬁgure legends.
RESULTS
EFhd2 Protein and mRNA Levels Are Reduced in
the Frontal Cortex in Dementia
EFhd2 had previously been linked to tau pathology in
dementia in a mouse model for FTLD as well as in AD (11, 12).
Because AD and FTLD are dementias with different etiologies,
these previous ﬁndings warranted further investigation into
the role played by EFhd2 in these diseases. Therefore, we
compared the protein expression of EFhd2 in human brain tis-
sues from individuals with different types of dementia with tau
pathology, namely, AD and FTLD-tau and Pick disease, with
that in nondemented controls. Protein levels of EFhd2 were
analyzed by Western blotting in both frontal cortex as well as
hippocampus because both brain regions are affected by their
respective neurodegenerative diseases. The analysis revealed a
reduction in EFhd2 protein levels in the frontal cortex from AD
and both types of FTLD-tau compared with controls (Fig. 1A, C);
these changes were conﬁrmed by quantitative real-time PCR
(Fig. 1E), suggesting a speciﬁc reduction of EFhd2 expression
in these tissues. Notably, however, no changes in EFhd2 pro-
tein levels were observed in hippocampi (Fig. 2).
Because of its link to hyperphosphorylated tau (12), we
next tested if changes in EFhd2 expression levels correlated
with the amount of tau pathology in these brain tissues. The
abundance of hyperphosphorylated tau was detected by anti-
body clones CP-13 (phosphorylated Ser-202), RZ3 (phos-
phorylated Thr-231), and PHF-1 (phosphorylated Ser-394/404)
in the previously studied samples. As expected, extensive tau
hyperphosphorylation could be detected at all phosphorylation
sites in the frontal cortex as well as hippocampal tissues from
samples from AD and both forms of FTLD-tau (Figs. 1B, 2B).
However, the amount of tau phosphorylation detected by
Western blotting did not correlate with the abundance of
EFhd2 protein in individual samples (Figs. 1D, 2D).
We therefore asked if changes in EFhd2 protein ex-
pression are limited to dementias with tau pathology. To answer
this question, EFhd2 protein abundance was compared be-
tween nondemented controls and cases with tau-negative FTLD
(FTLD-TDP Type B). As in the previously studied tau-positive
cases, signiﬁcantly lower levels of EFhd2 protein were detected
in the frontal cortex tissues in FTLD-TDB Type B cases when
compared with nondemented controls (Fig. 3A, B). Again, no
signiﬁcant changes in EFhd2 levels could be detected in hip-
pocampal tissues from the same cases (Fig. 3A, C). The ab-
sence of tau pathology was conﬁrmed by Western blotting for
tau phosphorylated at Ser-394/404 (PHF-1 epitope), which had
clearly been detected in AD and FTLD-tau (Fig. 3A, bottom).
Together, these results demonstrate that EFhd2 expres-
sion levels are altered in the frontal cortex in patients with
different types of dementia involving this brain region. Thus,
this ﬁnding ﬁts with the idea of a frontal cortexYrelated role of
EFhd2 in cognitive processes (12Y15). Whereas tau pathology
is a common feature of some of the dementia cases studied
here, dysfunction and aggregation of tau itself caused by its
hyperphosphorylation per se were not linked to these changes.
EFhd2 Is Expressed in Neurons in Brain Tissues
EFhd2 protein expression in neurons of the brain has
previously been described (11, 24, 26), but its expression and
function have also been linked to cells of the immune system
(26, 27), muscle (28), and epithelial cells (22, 23). Therefore,
we wanted to verify that EFhd2 expression was exclusively
neuronal. As expected, immunohistochemistry revealed EFhd2-
labeled cells with neuronal morphology in human brain samples
(Fig. 4-I); its neuronal location could be conﬁrmed by double
immunoﬂuorescence for EFhd2 and the neuronal marker NeuN
Borger et al J Neuropathol Exp Neurol  Volume 73, Number 12, December 2014
 2014 American Association of Neuropathologists, Inc.1170
Copyright © 2014 by the American Association of Neuropathologists, Inc. Unauthorized reproduction of this article is prohibited.
FIGURE 1. EFhd2 protein levels in the frontal cortex are reduced in tauopathies. (A)Western blot images of EFhD2 in human frontal
cortex tissue RIPA buffer extracts from nondemented controls, individuals with Alzheimer disease (AD), Pick disease (Pick’s), and
frontotemporal dementia with tau mutations (FTLD-tau). Western blots run with a 293T-cell line lysate loaded as a calibrator on
each gel. Beta-actin was used as a loading control. (B) Western blot analysis of total and phosphorylated Tau protein in human
frontal cortex samples. (C) Quantification of EFhd2 protein bands by densitometry, n = 3 for each sample. Error bars = SEM. *** p G
0.001 compared with control with 1-way ANOVA and Dunnett post hoc test. (D) Scatter plots of densitometry values for EFhd2
against values for each of the phosphorylated Tau antigens (PHF-1, CP-13, RZ3). Linear regression was done in GraphPad prism and
showed no correlation between EFhd2 and any of the phospho-tau antigens. (E) Quantitative real-time PCR for EFhd2, quantified
by the $$-Ct method. Actin and glyceraldehyde 3-phosphate dehydrogenase were used as housekeeping genes. * p G 0.05, ** p G
0.01 compared with control with 1-way ANOVA and Dunnett post hoc test.
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in adult mouse brain tissue (Fig. 4-II). In agreement with recent
mRNA expression data (24), abundant EFhd2 labeling was
present in the forebrain (hippocampus, cortex, and subcortical
structures; Fig. 4-IIAYC) and 2 different antibodies against
EFhd2 exclusively labeled cells that were colabeled with NeuN
in the frontal cortex (Fig. 4-IIDYF, J, K). At the very least,
therefore, the vast majority of EFhd2 in the adult mouse brain,
and probably the human brain, is present in neurons.
Compartment-Speciﬁc Changes in EFhd2 Protein
Abundance
Having established its neuronal localization, we tested
whether changes in EFhd2 protein abundance are associated
with speciﬁc compartments in human brain tissue. To this
end, ﬁltered synaptoneurosomes were prepared from human
brain frontal cortex tissues from dementia and nondemented
control patients. Success of the fractionation procedure was
veriﬁed by Western blotting for PSD-95 as a marker for the
postsynaptic density and NeuN as a marker for neuronal cell
nuclei/cell bodies. We conﬁrmed that there was an absence, or
at least a signiﬁcant reduction, of NeuN in the synaptoneurosome
and nonsynaptic supernatant fractions and the accumulation of
PSD-95 in the synaptoneurosome fraction compared with the non-
synaptic supernatant (Figure, Supplemental Digital Content 1,
http://links.lww.com/NEN/A673). Samples with a signiﬁcant
amount of NeuN in the synaptoneurosome fraction (Figure,
Supplemental Digital Content 1, http://links.lww.com/NEN/A673)
were excluded from the analysis because this indicated in-
sufﬁcient fractionation of the tissue. We then compared
EFhd2 protein levels by Western blot analysis in each of the
fractions (total tissue homogenates, pelleted synaptoneuro-
somes, and nonsynaptic cytoplasmic supernatant). Note that
we did not assess an enrichment of EFhd2 in the synapto-
neurosome fraction because we expected EFhd2 to only par-
tially associate with this compartment based on earlier results
obtained by Purohit et al (24). Comparison of EFhd2 protein
levels between groups within each of the fractions again re-
vealed signiﬁcantly less EFhd2 in tissue homogenates from
FLTD-tau, Pick disease, and FTD-TDP Type B cases as com-
pared with controls (nonsigniﬁcant reduction in AD samples;
Fig. 5A, B, left), a ﬁnding which is in line with our earlier
results (Fig. 1). Whereas there was a tendency toward lower
levels of EFhd2 in dementia in synaptoneurosomes (Fig. 5B,
middle) as well as nonsynaptic cytoplasmic supernatants in
cases of Pick disease and AD (Fig. 5A, bottom; 5B, right),
changes in these fractions were not signiﬁcant. There were
no changes in the levels PSD-95 in tissue homogenates be-
tween groups (Figure, Supplemental Digital Content 2A, B,
left, http://links.lww.com/NEN/A674), which is consistent with
previous reports of variable effects of dementia on the post-
synaptic density (2); also, there were no signiﬁcant changes
of NeuN (Figure, Supplemental Digital Content 2A, B, right,
http://links.lww.com/NEN/A674). These ﬁndings do not indi-
cate the absence of synapse and neuronal loss in the dementia
tissues studied here. Extensive atrophy is generally observed at
the later stages of dementia (29), which translates into a net loss
of neurons and synapses but is no longer reﬂected by a relative
loss of neuronal and synaptic proteins compared with whole
tissue markers. Importantly, adjustment of EFhd2 densitometry
results to levels of NeuN in each sample, as a measure of po-
tential neuronal cell loss in dementia (30, 31), did not alter
the overall outcome (Figure, Supplemental Digital Content 2C,
http://links.lww.com/NEN/A674). These results indicate that
there are global changes in EFhd2 protein abundance that
are mainly associated with cell bodies and neurites. We also
observe EFhd2 protein in the synaptic compartment, indicating
that it could be playing a role in synaptic processes in the
human brain.
EFhd2 Is Present in Neuronal Growth Cones and
Nascent Presynaptic Structures in Developing
Neurons In Vitro and Affects Synapse Formation
The role of EFhd2 in neuronal function has not been
investigated in detail. A recent report revealed that a loss of
EFhd2 does not have a direct impact on synaptic function, but
that it does affect transport along microtubules in neuronal
cultures (24). Studies in other cell types have found EFhd2 at
the leading edge of cells where it inﬂuences lamellipodia
formation (22, 23). Therefore, we investigated the potential
association of EFhd2 with growth cones, which represent the
leading edge of neurons, and synapses in developing neuronal
cultures. As predicted, coimmunocytochemistry for EFhd2 with
tau, tubulin, or (ﬁlamentous) actin in cortical neuronal cultures
clearly showed an accumulation of EFhd2 at the tip of neuro-
nal growth cones (Fig. 6A). A recent study demonstrated that
EFhd2 can also be associated with the synaptic compartment
in the rodent brain and in mature neuronal cultures (24). In
addition to this, coimmunoﬂuorescence staining with the pre-
synaptic marker synapsin 1a/b in neuronal cultures revealed that
EFhd2 can be present at nascent synaptic structures as early as
8 DIVVat a time before the recruitment of postsynaptic ele-
ments in vitro (Fig. 6B, arrows).
The recruitment of EFhd2 to neuronal growth cones
raised the possibility that EFhd2 could have a function in
neurite development. To test this hypothesis, overexpression
of EGFP-EFhd2 or EGFP alone or knockdown of EFhd2 was
induced in primary cortical neurons by lentiviral infection at
1 DIV. Successful expression of EGFP-EFhd2 or EGFP and
FIGURE 2. EFhd2 protein levels are not altered in the hippocampi of human tauopathy patients. (A)Western blots showing EFhd2
protein levels in human hippocampal tissue RIPA buffer extracts from nondemented controls and individuals with Alzheimer disease
(AD), Pick disease (Pick’s), and frontotemporal dementia with tau mutations (FTLD-tau). Western blot were repeated 3 times with a
293T-cell line lysate loaded as a calibrator on each gel. Beta-actin was used as a loading control. (B)Western blot analysis of total and
phosphorylated tau protein in human frontal cortex samples. (C) Quantification of EFhd2 protein bands by densitometry, n = 3 for
each sample. Error bars = SEM. (D) Scatter plots of densitometry values for EFhd2 against values for each of the phosphorylated Tau
antigens (PHF-1, CP-13, RZ3). Linear regression was done in GraphPad prism and showed no correlation between EFhd2 and any of
the phospho-tau antigens.
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EFhd2 knockdown were conﬁrmed in 3 DIV cultures by ﬂuo-
rescence imaging (Fig. 7A) and Western blotting (Fig. 7C),
respectively. The effect of this modulation of EFhd2 expres-
sion on the outgrowth neurites in cortical neurons was then
tested by quantiﬁcation of the length of MAP2-labeled neurites
per cell at 3 DIV. Interestingly, EGFP-EFhd2 overexpres-
sion or EFhd2 knockdown did not have any effect on the
length of neurites developed until 3 DIV (Fig. 7B) or at a
later stage at 8 DIV (Figure, Supplemental Digital Content 3,
http://links.lww.com/NEN/A675).
Because of its partial association with nascent synapses
in addition to neuronal growth cones in vitro (Fig. 6B), a
potential effect of the loss of EFhd2 on the formation of
synapses in cortical neuronal cultures was tested. Presynaptic
(synapsin 1a/b) puncta in total per micrometer of A3-tubulinY
labeled neurites were counted in mature neuronal cultures at
15 to 16 DIV after lentiviral knockdown of EFhd2 or infection
with a control shRNA (Fig. 7D). Indeed, this analysis re-
vealed that knockdown of EFhd2 facilitates the development
of a larger number of synapses in vitro (Fig. 7E). At the same
time, there was no difference in the ratio comparing mature
synapses identiﬁed by the colocalization of synapsin and
PSD95 with nascent structures labeled by synapsin alone
(Fig. 7F). These results suggests that a downregulation of
EFhd2 in neurons enhances their capacity to induce the for-
mation of new functional synapses but does not affect their
ability to convert these to mature synapses by recruiting post-
synaptic densities.
DISCUSSION
EFhd2 is a novel calcium-binding protein; its biologic
roles in the CNS have only recently started to emerge. Here
we show that EFhd2 protein and mRNA levels are reduced in
the frontal cortex in AD, Pick disease, and FTLD with tau
pathology and that protein levels are also reduced in FTLD-
TDP Type B (without tauopathy) compared with nondemented
controls (Figs. 1, 3). We conﬁrmed these ﬁndings in separate
sets of experiments using different methods for protein ex-
traction; EFhd2 protein levels were also found to be reduced in
synaptoneurosome preparations from dementia compared with
control patients (Fig. 5).
FIGURE 3. EFhd2 protein levels in the frontal cortex are reduced in patients with dementia without tauopathy. (A) Western blots
showing EFhd2 protein levels in human frontal cortex (left) and hippocampal (right) tissue RIPA extracts from nondemented
controls and individuals with frontotemporal lobar degeneration FTLD-TDP Type B. A sample from AD frontal cortex was run as a
calibrator and phospho-tauYpositive control on each gel. No calibrator sample was run for EFhd2 and actin detection in hippo-
campal samples because all samples were run on the same SDS-PAGE. Beta-actin was used as a loading control. (B) Quantification
of EFhd2 protein bands by densitometry in frontal cortex samples. * p G 0.05 with all data points (left), *** p G 0.001 without
encircled outlier (right), compared with control by t test. (C) Quantification of EFhd2 protein bands in samples from human
hippocampus from nondemented controls and individuals with FTLD-TDP Type B.
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FIGURE 4. (I) Immunohistochemistry (IHC)with a rabbit polyclonal antibody (RbpAb) on human brain tissues for EFhd2. Scale bars = 100Km
(left); 50Km (right). (II) IHC onmouse brain for NeuN (red: A, D, G, J), EFhd2 with a goat polyclonal antibody (green: B, E, H), and
merge (C, F, I). (AYC) EFhd2 is present in neuronal layers of the hippocampus (cornu ammonis [CA]), cortex (Cx), and subcortical
structures (striatum [ST]). Scale bar = 250 Km. (DYF) Expression in the frontal cortex is restricted to anti-NeuNYlabeled neurons. Scale
bar = 50 Km. (GYI) No primary antibody, merge with 4¶,6-diamidino-2-phenylindole. Scale bar = 100 Km. (JYL) Similar results were
obtained using an RbpAb against an N-terminal epitope of EFhd2 stained in the frontal cortex (red). Scale bar = 50 Km.
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FIGURE 5. EFhd2 protein levels in the frontal cortex are reduced in total homogenates from patients with dementia but not in
synaptoneurosomes. (A) Western blots showing EFhd2 protein levels in human frontal cortex tissue extracts from nondemented
controls and individuals with Alzheimer disease (AD), frontotemporal lobar degeneration (FTLD)-tau (FTLD-tau), Pick disease, or
FTLD-TDP Type B (FTLD-TDP). Beta-actin was used as a loading control for homogenates and nonsynaptic fractions; PSD-95 was
used as a loading control for synaptoneurosome fractions. (B) Quantification of EFhd2 protein bands by densitometry. Error bars =
SEM.Homogenate: 1-way ANOVA, p = 0.0301; * p G 0.05 comparedwith control by usingDunnett post hoc test. Synaptoneurosomes:
1-way ANOVA, p = 0.1108. Nonsynaptic: 1-way ANOVA, p = 0.4848.
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FIGURE 6. EFhd2 is present in neuronal growth cones andnascent presynaptic structures indevelopingneurons. (A)Coimmunofluorescence
of EFhd2with cytoskeletal proteins. Top: Confocal images of EFhd2 (green) and Tau (red) in 10 days in vitro (DIV) neurons. Scale bar = 5Km.
Middle: epifluorescence images of EFhd2 (green) and tubulin (red) in 3 DIV neurons. Scale bar = 10 Km. Bottom: confocal images of EFhd2
(green) and Phalloidin (red) in 7 DIV neurons. Scale bar = 5 Km (top, bottom). (B) Immunocytochemistry of EFhd2 (rabbit polyclonal
antibody, red) and synapsin (green) on 8 DIV neurons. Yellow arrows indicate foci of colocalization. Scale bar = 5 Km (bottom).
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Interestingly, no signiﬁcant changes in EFhd2 protein
abundance could be observed in the hippocampus of either
FTLD or AD cases (Figs. 2, 3), although this brain region is
markedly affected in AD alongside the neocortex (32, 33). We
showed by immunohistochemistry that EFhd2 is strongly
expressed in the hippocampus (Fig. 4-IIA-C), which is in
agreement with earlier studies (12, 24). However, it is possi-
ble that EFhd2 has functions relevant to cognitive processes in
neuronal subtypes that are present in the neocortex but not the
hippocampal allocortex, and it is also worth noting that its role
in the hippocampus has not been investigated to date. Most
studies involving EFhd2 in the CNS have analyzed frontal
cortex tissues and have investigated neuropathologic pro-
cesses that speciﬁcally affect the frontal cortex, such as FTLD
(12), schizophrenia (14), and psychiatric conditions linked to
suicide (15). Our present data support the notion that EFhd2
might play a signiﬁcant role in the function of the frontal
cortex, and that changes in its expression or posttranslational
modiﬁcation could be related to common processes underly-
ing (pre)frontal cortex pathology.
The observations that protein and mRNA expression
changes are present in tauopathies as well as tau-negative
FTLD-TDP Type B and that there is no correlation between
the amount of tau hyperphosphorylation and levels of EFhd2
in tauopathies (Figs. 1, 2) argue against a causative relation-
ship between the two. Studies by Vega et al (12) and Ferrer-
Acosta et al (11) identiﬁed EFhd2 as a protein coaggregating
with pathologic tau in AD; a mouse model for FTLD also
suggested an association with tau by coimmunoprecipitation
from nondemented control brain tissue (12). Its interaction
with nonpathologic tau species under physiologic conditions
has, however, not been studied. Our data of both EFhd2 and
tau proteins at the tip of neuronal growth cones in cultured
neurons (Fig. 6A, top) support the idea of a functional inter-
action between them. We saw a similar relationship between
EFhd2 and tubulin as well as actin (Fig. 6A, middle, bottom).
Indeed, Purohit et al (24) demonstrated a direct effect of
EFhd2 on microtubule transport in the absence of tau, and
previous studies in non-neuronal cells established EFhd2 as
an actin-binding protein involved in the regulation of actin
bundling (22, 23, 34). Together, these ﬁndings imply that a
functional or physical interaction between EFhd2 and tau
might also be caused by their common interaction with tu-
bulin and actin and put the role of EFhd2 in the regulation of
cytoskeletal function into the center of interest.
EFhd2 is partially located in synapses, but it is most
strongly associated with neuronal cell bodies and neurites
(24). EFhd2 protein abundance are global and affect not only
cell bodies and neurites in brain tissues affected by dementia
but also synaptic compartment (Fig. 5). The observed reduc-
tion of EFhd2 mRNA levels supports this view (Fig. 1E).
Because changes tended toward a reduction of EFhd2 in de-
mentia in all fractions studied (Fig. 5B), our results also imply
that there is no major redistribution of EFhd2 to or from the
synaptoneurosomal compartment associated with dementia. It
has to be acknowledged, however, that these ﬁndings are based
on crude synaptoneurosome preparations by ﬁltration from
frozen tissues (as applied by Tai et al [25]) and merely indicate
overall changes. Purohit et al (24) showed that EFhd2 is asso-
ciated with the cytosolic as well as the plasma membrane frac-
tion in synaptosomes isolated by differential centrifugation. In
light of this, future more extensive and precise analyses of
EFhd2 distribution and its potential changes in localization in
neuropathologic conditions by immunoelectron microscopy
and the isolation of synaptosomes and their subfractionation by
density gradient centrifugation from fresh tissues would ad-
dress these issues.
An initial study analyzing the effect of EFhd2 on syn-
aptic function found no impact on the turnover of synaptic
vesicles in cultured neurons (24). We show here that knock-
down of EFhd2 does, however, boost the formation of new
synaptic connections in cortical neuronal cultures (Fig. 7E, F),
whereas it does not affect the growth of neurites (Fig. 7). In-
terestingly, EFhd2 has been shown to affect vesicular trans-
port along microtubules (24); thus, it is conceivable that this
function is underlying its effect on synapse development,
which strongly depends on cytoskeletal rearrangements (in-
cluding tau [35]) and is modulated by signaling cascades that
EFhd2 has been linked to in other cell types, such as PI3K
signaling (36, 37). Importantly, the formation of new synaptic
connections is not restricted to embryonic development but is
also important in the adult brain, and failure to maintain cur-
rent and develop new synapses is strongly linked to dementia
(1). Possible functions of EFhd2 could be in synapse forma-
tion (e.g. pruning) during development and/or synapse main-
tenance in the adult brain. In this context, it is interesting to
note that Purohit et al (24) found higher levels of EFhd2 ex-
pression in the adult mouse brain compared with embryonic
brain tissues, which our own preliminary RT-PCR data could
conﬁrm (not shown). This suggests that the function of EFhd2
might primarily be in the postnatal or adult brain. Synaptic
plasticity is also increasingly being studied in the frontal
cortex with regard to dementia and other psychiatric disor-
ders, for example, schizophrenia and mood disorders (38).
FIGURE 7. Neurite development in expression short hairpin RNA (shRNA) targeting EFhd2 (shEFhd2) and enhanced green fluo-
rescent protein (EGFP)-EFhd2 transgenic neuronal cultures. (A) Representative images of primary cortical neurons infected with
lentiviral supernatants for shEFhd2 or a scrambled control (shScr) overexpression of EGFP-EFhd2 or EGFP alone. Cells were infected
at 1 day in vitro (DIV) and fixed and stained for microtubule-associated protein 2 (MAP2) at 3 DIV. Scale bar = 50 Km. (B)
Quantification of anti-MAP2Yimmunostained neurites from 10 fluorescence images (20 magnifications) per group. n.s., non-
significant by 2-tailed t test. Results are representative of 3 independent experiments. (C) Verification of EFhd2 knockdown by
Western blotting. (D) Immunocytochemistry for synapsin and tubulin in neurons with EFhd2 knockdown (shEFhd2, top) or ex-
pression scrambled control shRNA (bottom). Scale bar = 10 Km. (E) Quantification of the number of synapsin puncta per 10 Km,
labeled for tubulin in 3 independent experiments. ** p G 0.01 by 2-tailed t test, error bars = SEM, n = 10 fields of view for each
experiment. (F) Quantification of the number of mature synapses labeled with synapsin and PDS-95 colocalization compared with
the total number of synapsin puncta in the same cultures analyzed in E. Error bars = SEM, n = 10. Nonsignificant by 2-tailed t test.
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Our data together with the earlier studies raise the possibility
that EFhd2 expression levels impact on these processes in the
brain, speciﬁcally in the frontal cortex, and that its own regula-
tion of expression or posttranslational modiﬁcation (13, 21, 39)
could therefore be important. A recent study suggests that such
posttranslational modiﬁcation could indeed be relevant for
neurodegenerative diseases, that is, phosphorylation of EFhd2
by Cdk5 was found to occur in AD and to affect its calcium-
binding activity (13). Cdk5 itself has previously been linked to
tauopathy (40), speciﬁcally in AD (41Y43), and to other neu-
rodegenerative diseases such as Parkinson disease (44, 45). The
positive impact of EFhd2 knockdown on microtubule trans-
port (24) and synapse numbers (Fig. 7E, F) implies that, when
present, EFhd2 might enable the integration of signaling cues
that decide the fate of nascent synapses; this spatiotemporal
regulation is likely to be of pivotal importance for correct
neuronal network function and hence cognitive processes. A
hypothesis based on current data on the role of EFhd2 in neu-
rons in the brain and how it might inﬂuence neuropathologic
processes (or be inﬂuenced by them) is depicted in Figure 8.
The mechanisms underlying the reduction of EFhd2
expression in the brain have not been elucidated so far. It has
FIGURE 8. Hypothesis on the function of EFhd2 in the brain. EFhd2 inhibits kinesin-mediated anterograde microtubule transport in
neurons. This could also involve physical or functional interaction with the microtubule binding protein tau. It also negatively regulates
the formation of synapses either directly through its effect on actin remodeling and a potential function in growth cones other than
neurite outgrowth or indirectly through its negative impact onmicrotubule transport. EFhd2 is a Ca2+-binding protein, and its function is
regulated by intracellular Ca2+. Pathologically elevated Ca2+ might therefore impact on EFhd2 function. Ca2+ is furthermore involved in
signaling mechanisms activating the Cdk5 protein kinase, which inhibits EFhd2 by phosphorylation of residues relevant for its Ca2+-
binding activity. Pathologically elevated Ca2+ levels and aberrant activation of Cdk5 have previously been described in neurodegener-
ative diseases. Changes in EFhd2 expression as well as synapse loss are associated with dementia and other neurodegenerative diseases
affecting the frontal cortex. EFhd2might be involved in processes such as synaptic pruning or morphologic plasticity in this brain region,
and its loss might have a profound impact on the balance of synapse maintenance and exacerbate or be a sign of synaptic pathology.
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been reported that EFhd2 expression is controlled by path-
ways involving protein kinase C (A/D/ X), as well as nuclear
factor-JB in immune cells (17, 18). Therefore, it is plausible that
similar mechanisms would exist in neuronal cells. Interestingly,
neurotrophic signaling, which activates signaling cascades
involving protein kinase C and nuclear factor-JB, is known to
be disturbed in dementia (46Y48), and this might contribute to
the observed changes in EFhd2 expression. Further studies
delineating the pathways involved in the regulation of EFhd2
expression in the brain are needed and might elucidate new
pathways that orchestrate the maintenance of synapses in the
frontal cortex. Consequently, these studies will help to under-
stand the context of EFhd2 activity in neurons and determine
whether its dysregulation could be an indicator of synaptic pa-
thology in the human frontal cortex.
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